Jessica Castrillon Lal1,2, Sherry-Ann Brown3, Patrick Collier2,4, Feixiong Cheng5,6,7. 1. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. 2. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, 44195, USA. 3. Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. 4. Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland, OH, 44195, USA. 5. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. chengf@ccf.org. 6. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, 44195, USA. chengf@ccf.org. 7. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA. chengf@ccf.org.
Abstract
BACKGROUND: Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several cancer types, the incidence of immune-related cardiovascular (CV) adverse events poses an additional health concern and has been reported. METHODS: We performed a retrospective analysis of the FDA Adverse Event Reporting System data of suspect product reports for immunotherapy and classical chemotherapy from January 2010-March 2020. We identified 90,740 total adverse event reports related to immune checkpoint inhibitors and classical chemotherapy. RESULTS: We found that myocarditis was significantly associated with patients receiving anti-program cell death protein 1 (PD-1) or anti-program death ligand 1 (PD-L1), odds ratio (OR) = 23.86 (95% confidence interval [CI] 11.76-48.42, (adjusted p-value) q < 0.001), and combination immunotherapy, OR = 7.29 (95% CI 1.03-51.89, q = 0.047). Heart failure was significantly associated in chemotherapy compared to PD-(L)1, OR = 0.50 (95% CI 0.37-0.69, q < 0.001), CTLA4, OR = 0.08 (95% CI 0.03-0.20, q < 0.001), and combination immunotherapy, OR = 0.25 (95% CI 0.13-0.48, q < 0.001). Additionally, we observe a sex-specificity towards males in cardiac adverse reports for arrhythmias, OR = 0.81 (95% CI 0.75-0.87, q < 0.001), coronary artery disease, 0.63 (95% CI 0.53-0.76, q < 0.001), myocardial infarction, OR = 0.60 (95% CI 0.53-0.67, q < 0.001), myocarditis, OR = 0.59 (95% CI 0.47-0.75, q < 0.001) and pericarditis, OR = 0.5 (95% CI 0.35-0.73, q < 0.001). CONCLUSION: Our study provides the current risk estimates of cardiac adverse events in patients treated with immunotherapy compared to conventional chemotherapy. Understanding the clinical risk factors that predispose immunotherapy-treated cancer patients to often fatal CV adverse events will be crucial in Cardio-Oncology management.
BACKGROUND: Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several cancer types, the incidence of immune-related cardiovascular (CV) adverse events poses an additional health concern and has been reported. METHODS: We performed a retrospective analysis of the FDA Adverse Event Reporting System data of suspect product reports for immunotherapy and classical chemotherapy from January 2010-March 2020. We identified 90,740 total adverse event reports related to immune checkpoint inhibitors and classical chemotherapy. RESULTS: We found that myocarditis was significantly associated with patients receiving anti-program cell death protein 1 (PD-1) or anti-program death ligand 1 (PD-L1), odds ratio (OR) = 23.86 (95% confidence interval [CI] 11.76-48.42, (adjusted p-value) q < 0.001), and combination immunotherapy, OR = 7.29 (95% CI 1.03-51.89, q = 0.047). Heart failure was significantly associated in chemotherapy compared to PD-(L)1, OR = 0.50 (95% CI 0.37-0.69, q < 0.001), CTLA4, OR = 0.08 (95% CI 0.03-0.20, q < 0.001), and combination immunotherapy, OR = 0.25 (95% CI 0.13-0.48, q < 0.001). Additionally, we observe a sex-specificity towards males in cardiac adverse reports for arrhythmias, OR = 0.81 (95% CI 0.75-0.87, q < 0.001), coronary artery disease, 0.63 (95% CI 0.53-0.76, q < 0.001), myocardial infarction, OR = 0.60 (95% CI 0.53-0.67, q < 0.001), myocarditis, OR = 0.59 (95% CI 0.47-0.75, q < 0.001) and pericarditis, OR = 0.5 (95% CI 0.35-0.73, q < 0.001). CONCLUSION: Our study provides the current risk estimates of cardiac adverse events in patients treated with immunotherapy compared to conventional chemotherapy. Understanding the clinical risk factors that predispose immunotherapy-treated cancerpatients to often fatal CV adverse events will be crucial in Cardio-Oncology management.
Authors: Joe-Elie Salem; Ali Manouchehri; Melissa Moey; Bénédicte Lebrun-Vignes; Lisa Bastarache; Antoine Pariente; Aurélien Gobert; Jean-Philippe Spano; Justin M Balko; Marc P Bonaca; Dan M Roden; Douglas B Johnson; Javid J Moslehi Journal: Lancet Oncol Date: 2018-11-12 Impact factor: 41.316
Authors: Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi Journal: Cardiovasc Res Date: 2019-04-15 Impact factor: 10.787
Authors: Jacob Schachter; Antoni Ribas; Georgina V Long; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian Blank; Teresa M Petrella; Omid Hamid; Honghong Zhou; Scot Ebbinghaus; Nageatte Ibrahim; Caroline Robert Journal: Lancet Date: 2017-08-16 Impact factor: 79.321
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam Journal: Lancet Oncol Date: 2015-02-20 Impact factor: 41.316
Authors: Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Vincenzo Quagliariello; Margherita Passariello; Annabella Di Mauro; Ciro Cipullo; Andrea Paccone; Antonio Barbieri; Giuseppe Palma; Antonio Luciano; Simona Buccolo; Irma Bisceglia; Maria Laura Canale; Giuseppina Gallucci; Alessandro Inno; Claudia De Lorenzo; Nicola Maurea Journal: Front Cardiovasc Med Date: 2022-09-08